SK Hynix bets on AI demand with bumper $29bn US listing - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号)。如果该手机号尚未注册,将自动创建 FT中文网账号。短信可能需要几分钟送达,验证码15分钟内有效,请耐心等待:
请您阅读我们的用户注册协议和隐私权保护政策,点击下方按钮即视为您接受。
SK海力士

SK Hynix bets on AI demand with bumper $29bn US listing

South Korean chipmaker capitalises on central role in global AI boom
00:00

{"text":[[{"start":8.25,"text":"Chipmaker SK Hynix is to raise Won 45.5tn ($29bn) in a US listing, taking advantage of a surge in its share price sparked by its central role in the global AI boom."}],[{"start":21.1,"text":"The South Korean group said in a regulatory filing on Wednesday it planned to list American depositary receipts on the Nasdaq exchange next month."}],[{"start":30.6,"text":"It will be one of the largest such fundraisings by an Asian company, surpassing the initial public offering of China’s Alibaba more than a decade ago."}],[{"start":39.900000000000006,"text":"SK Hynix has outmuscled better-known chipmakers, including rival Samsung Electronics, to claim more than half of the global market for high-bandwidth memory chips, which allow the massive volumes of data required for AI to flow at high speeds."}],[{"start":55.60000000000001,"text":"The funds raised through the US offering will be used to support construction of new domestic chip plants, the company said."}],[{"start":63.650000000000006,"text":"SK Hynix is the primary HBM supplier to Nvidia and was recently selected by Microsoft for its own proprietary AI chips."}],[{"start":72.25,"text":"Shortages of HBM, as well as less powerful DRam and Nand memory chips, are propelling prices higher, with SK Hynix reaping the benefits. In April, the company reported record first-quarter operating profit of Won37.6tn, a fivefold jump from a year earlier."}],[{"start":90.15,"text":"Samsung and SK Hynix have both topped $1tn in market capitalisation and are among the 20 biggest companies globally."}],[{"start":98.10000000000001,"text":"SK Hynix this week overtook its rival in market capitalisation, helped by its strength in advanced memory products. Its shares have quadrupled in value so far this year."}],[{"start":108.7,"text":"The two companies now account for more than half of South Korea’s total market value, fuelling concerns about the stock market’s growing dependence on the two companies amid heightened volatility in recent weeks."}],[{"start":120.55,"text":"SK Hynix’s ADRs are expected to begin trading on July 10. The size of the offering may change following bookbuilding, but the shares initially offered will represent 2.5 per cent of SK Hynix’s outstanding stock, according to analysts."}],[{"start":136.85,"text":"Analysts said a US listing could improve access for global investors and narrow SK Hynix’s valuation gap against Micron and other US peers."}],[{"start":146.6,"text":"Taiwanese chipmaker TSMC, which first listed ADRs in 1997, has become a favourite among US investors seeking exposure to the AI supply chain."}],[{"start":156.7,"text":"SK Hynix shares jumped 2.7 per cent in after-hours trading on Wednesday after the regulatory filing."}],[{"start":163.89999999999998,"text":"SK Hynix and Samsung are in talks with the South Korean government to develop a new semiconductor production cluster."}],[{"start":171.34999999999997,"text":"Presidential policy adviser Kim Yong-beom said on Wednesday that the two companies needed to accelerate construction of new chipmaking facilities, bringing forward development timelines by more than a decade and targeting completion around 2034-35."}],[{"start":195.09999999999997,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1782300434_7232.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

FT社评:星链风波凸显欧洲亟须在太空领域迎头赶上

美国科技遥遥领先,但布鲁塞尔仍需建立自己的卫星网络并具备发射能力。

新加坡寻求追究相关公司责任,应对十年来最严重空气污染

政府威胁将对10家企业采取法律行动,称这些企业是邻国印尼山火的幕后推手,而山火造成的烟霾正在困扰新加坡。

美债收益率冲击下,欧洲必须自寻出路

埃里安:欧洲不能只盼着大西洋彼岸的借贷成本回落,它必须着手解决自身问题。

AI与通胀:央行行长该担忧到什么程度?

凯恩斯:这取决于一个价值万亿美元问题的答案:AI是否真能带来预期的生产力提升?

印度企业界的乐观情绪站得住脚吗?

印度企业界公开表达的乐观情绪,与家庭和投资者的焦虑情绪之间的落差日益明显。

Lex专栏:中国药企在药品开发领域获得一席之地

外国制药集团如今开始购买中国本土开发创新药物的授权。
设置字号×
最小
较小
默认
较大
最大
分享×